Table 3.
Univariate and multivariate analyses of survival for pembrolizumab-based therapy
| Variables | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| mPFS (months) | p | HR for PFS | p | mOS (months) | p | HR for OS | p | |
| Age | ||||||||
| ≤60 years | 3.0 | 0.845 | 12.0 | 0.381 | ||||
| >60 years | 3.0 | NR (>18) | ||||||
| Sex | ||||||||
| Male | 3.0 | 0.95 | 16.0 | 0.957 | ||||
| Female | 3.0 | 7.0 | ||||||
| Melanoma subtype | ||||||||
| CSD/non-CSD | 3.0 | 0.961 | 16.0 | 0.82 | ||||
| Acral | 3.0 | NR (>19) | ||||||
| Mucosal | 3.0 | 12.0 | ||||||
| Uveal | 3.0 | NR (>6) | ||||||
| ECOG | ||||||||
| 0–1 | 3.0 | 0.009 | 1 | 0.167 | 16.0 | 0.008 | 1 | 0.013 |
| 2 | 2.0 | 3.2 | 3.0 | 6.4 | ||||
| LDH level | ||||||||
| ≤ULN | 9.0 | 0.0003 | 1 | 0.029 | 16.0 | 0.013 | 1 | 0.025 |
| >ULN | 3.0 | 2.5 | 7.0 | 6.3 | ||||
| Liver Metastasis | ||||||||
| No | 3.0 | 0.008 | 0.81 | NR (>19) | 0.001 | 0.348 | ||
| Yes | 3.0 | 6.0 | ||||||
| Brain metastasis | ||||||||
| No | 3.0 | 0.9 | 12.0 | 0.613 | ||||
| Yes | 9.0 | NR (>16) | ||||||
| BRAF mutation | ||||||||
| Yes | 3.0 | 0.927 | 16.0 | 0.282 | ||||
| No | 3.0 | 10.0 | ||||||
| Previous treatment | ||||||||
| No | 3.0 | 0.96 | 16.0 | 0.901 | ||||
| Yes | 3.0 | NR (>19) | ||||||
| Relative lymphocyte count | ||||||||
| ≤25.2% | 3.0 | 0.001 | 2.6 | 0.034 | 6.0 | 0.001 | 7.8 | 0.06 |
| >25.2% | NR (>19) | 1 | NR (>19) | 1 | ||||
| Relative eosinophil count | ||||||||
| ≤2.2% | 3.0 | 0.041 | 1 | 0.227 | 7.0 | 0.004 | 3.2 | 0.016 |
| >2.2% | 5.0 | 0.4 | NR (>19) | 1 | ||||
| Treatment-related rash/vitiligo | ||||||||
| No | 3.0 | 0.001 | 0.077 | 7.0 | 0.003 | 66.8 | 0.007 | |
| Yes | NR (>19) | NR (>19) | 1 | |||||
NR not reached